Results Of Phase I Study Show Novel, Investigational PA65020 Compound Significantly Decreased Risk Of Upper Gastrointestinal Damage In Healthy Adults
Links shared publicly online about this topic.
- 1,644total visits
Results Of Phase I Study Show Novel, Investigational PA65020 Compound Significantly Decreased Risk Of Upper Gastrointestinal Damage In Healthy Adults
POZEN Inc. (NASDAQ: POZN) announced the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin (EC-ASA) and immediate-release omeprazole known as PA6
View full resource at medicalnewstoday.com
Tags: GERD Medication, Zollinger-Ellison Syndrome Medication, Heartburn Medication, H pylori Infection Medication, Erosive Esophagitis Medication, Stomach Ulcer Medication, Duodenal Ulcer Medication, Aspirin
Most Recently Shared on October 28, 2009 at 5:31 pm By:
Results Of Phase I Study Show Novel, Investigational PA65020 Compound Significantly Decreased Risk Of Upper Gas.. http://bit.ly/DVSZ1
Advertisement
